Faculty

Back to Index
Joseph Landolph, PhD
Associate Professor of Molecular Microbiology & Immunology
Molecular Microbiology and Immunology
CRL 1303 Mission Rd Off Campus Los Angeles
+1 323 224 7781

Overview

Joseph R. Landolph, Jr., Ph. D.,was born and raised in Clifton Heights, Pennsylvania, a suburb of Philadelphia, Pennsylvania. He graduated from Clifton Heights High School in Clifton Heights, Pennsylvania, in June, l966, as Valedictorian of his class. Dr. Landolph received a B. S.Degree in Chemistry from Drexel University in Phila., Pa. in l971, graduating second in his class of Chemistry Majors. He then received a Ph. D. in Chemistry, majoring in Biophysical and Physical Chemistry, from the Univ. of California at Berkeley in l976, studying under the late Professor Melvin Calvin (Member of the U. S. National Academy of Sciences and a Nobel Laureate). For his Ph. D. thesis, Dr. Landolph studied BaP metabolism and BaP-induced cytotoxicity/morphological transformation in mouse liver epithelial/fibroblastic cells. He performed postdoctoral study in chemical mutagenesis and chemically induced morphological and neoplastic transformation and chemical carcinogenesis from l977-1980 at the University of Southern California (USC) under the late Professor Charles Heidelberger, who was a Member of the U. S. National Academy of Sciences. Dr. Landolph was appointed Assistant Professsor of Microbiology and Pathology in l982, and promoted to Associate Professor in l9787. He is currently Associate Professor of Molecular Microbiology and Immunology and Pathology, and a Member of the USC/Norris Comprehensive Cancer Center at the Keck School of Medicine, Associate Professor of Molecular Pharmacology and Pharmaceutical Sciences of the School of Pharmacy, and a Member of the Free Radical Institute, at USC in Los Angeles, California. His research interests include the molecular mechanisms of the carcinogenicity of insoluble, carcinogenic nickel compounds and of soluble and insoluble, carcinogenic Cr(VI) compounds, and activation of oncogenes/inactivation of tumor suppressor genes and de-regulation of global gene expression, in Ni-transformed C3H/10T1/2 (10T1/2) mouse mouse embryo cell lines. His laboratory has shown that 150 genes are differentially expressed in 10T1/2 cell lines transformed by insoluble green NiO and crystalline NiS. In these transformed cell lines, the ect-2 proto-oncogene is amplified and over-expressed, and the Wdr1 stress gene and the calnexin gene are over-expressed. We also found that the DRIP80 gene and the beta-centaurin-2 gene have become quiescent in the Ni-transformed 10T1/2 cell lines. Our current working model is that 6 proto-oncogenes have become activated, and 9 tumor suppressor genes have become quiescent, in Ni-transformed 10T1/2 cell lines. Each alternation of these 15 primary genes leads to differential expression of 10 additional genes, indicating that there are substantial changes in regulation of gene expression in Ni-transformed 10T1/2 mouse embryo cell lines. Dr. Landolph's laboratory has also studied the ability of insoluble nickel compounds and of soluble and insoluble Cr(VI) compounds to induce cytotoxicity and anchorage-independent transformation of cultured human diploid human fibroblasts. Dr. Landolph is an expert in chemically induced mutation and morphological/neoplastic transformation of mammalian cells. He has authored 65 scientific publications, given 204 invited scientific lectures, trained 105 B. S., 31 M. S., 5 Medical, and 14 Ph. D. students and 32 postdoctoral fellows, and hosted 10 faculty on sabbatical in his laboratory. He has reviewed grants for U. S. EPA, NIEHS, and Chemical Pathology/Al-Tox-4 Study Sections of NIH. He served as a member of: Carcinogen Identification Committee, Calif. EPA (1994-Present); Scientific Review Panel for Toxic Air Contaminants, Calif. Air Resources Board (2003-2011); Drinking Water (2003-2009), Human Health Research (2003), and STAA (2003-2006), Committees of U. S. EPA’s Science Advisory Board; U. S. EPA Board of Scientific Counselors’ Human Health Research Committee (2005-2006); and Natl. Acad. of Sciences Panel on U. S. EPA’s PCE Risk Assessment (2009-2010). He received the Merck Award in Chemistry (Drexel Univ.); ACS Postdoctoral Fellowship; and Edmundson Teaching Award (Dept. Path., USC). He has held research grants from EPA, NCI, and NIEHS.

Dr. Landolph has been a member of the Society of Toxicology from l985-Present. He received the ICI Traveling Lectureship Award from the Society of Toxicology in l990. He has served as a Member of the Graduate Student Awards Committee, Carcinogenesis Specialty Section, Society of Toxicology, from 1994-1999. He was elected Councilor, Carcinogenesis Specialty Section, Society of Toxicology, from 1997-1999. He was elected Vice-President Elect of the Metals Specialty Section for 1999-2000; Vice-President, Metals Specialty Section, 2000-2001; and President-Elect, Metals Specialty Section, 2001-2002. He also served as a Member of the Review Committee for Graduate Student/Postdoctoral Fellow Awards, 2000, Metals Specialty Section; Member of the Review Committee for Submissions to the SOT Program Committee from the Metals Specialty Section, 2002; President, Metals Specialty Section, 2002-2003; and Councilor, Metals Specialty Section, from 2003-2004. He was appointed a Member of the Regulatory Affairs and Legislative Assistance (RALA) Committee of the Society of Toxicology, from 2007-2010,

Awards

American Cancer Society, U. S. A. : American Cancer Society Postdoctoral Fellowship , l977-l979

Publications

Tseng CH, Chen CJ, Landolph JR. Diabetes and cancer: epidemiological, clinical, and experimental perspectives. Exp Diabetes Res. 2012; 2012:101802. View in: PubMed

Muggia FM, Peters GJ, Landolph JR. XIII International Charles Heidelberger Symposium and 50 Years of Fluoropyrimidines in Cancer Therapy Held on september 6 to 8, 2007 at New York University Cancer Institute, Smilow Conference Center. Mol Cancer Ther. 2009 May; 8(5):992-9. View in: PubMed

Clemens F, Verma R, Ramnath J, Landolph JR. Amplification of the Ect2 proto-oncogene and over-expression of Ect2 mRNA and protein in nickel compound and methylcholanthrene-transformed 10T1/2 mouse fibroblast cell lines. Toxicol Appl Pharmacol. 2005 Aug 7; 206(2):138-49. View in: PubMed

Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, Landolph J, Morrison H, Sonawane B, Shifflett T, Waters DJ, Timms B. Human prostate cancer risk factors. Cancer. 2004 Nov 15; 101(10 Suppl):2371-490. View in: PubMed

Verma R, Ramnath J, Clemens F, Kaspin LC, Landolph JR. Molecular biology of nickel carcinogenesis: identification of differentially expressed genes in morphologically transformed C3H10T1/2 Cl 8 mouse embryo fibroblast cell lines induced by specific insoluble nickel compounds. Mol Cell Biochem. 2004 Jan; 255(1-2):203-16. View in: PubMed

Clemens F, Landolph JR. Genotoxicity of samples of nickel refinery dust. Toxicol Sci. 2003 May; 73(1):114-23. View in: PubMed

Landolph JR, Verma A, Ramnath J, Clemens F. Molecular biology of deregulated gene expression in transformed C3H/10T1/2 mouse embryo cell lines induced by specific insoluble carcinogenic nickel compounds. Environ Health Perspect. 2002 Oct; 110 Suppl 5:845-50. View in: PubMed

Powered bySC CTSI